GlassScriptPhysician profile
Jasmine K Bajaj
NPI 1285992875
$7,991.14
in general payments reported to CMS, 2019-2025
45 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $560 · 2021: $802 · 2022: $1,155 · 2023: $1,606 · 2024: $1,599 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,755 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,755.28 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,621.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,045.88 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $548.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.84 | 2019-2025 | Jardiance, Tradjenta, Combivent Respimat |
| Pfizer INC. | $511.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $418.01 | 2019-2025 | Gardasil 9, Verquvo, Gardasil |
| Abbvie INC. | $399.23 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Sanofi-Aventis U.S. LLC | $348.69 | 2019-2023 | |
| Glaxosmithkline, LLC. | $281.96 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $259.96 | 2022-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $220.58 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $172.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $155.58 | 2019-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $151.87 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.03 | 2022-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Bajaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.